Sponsor pipeline

TG Therapeutics, Inc. clinical trial pipeline

Get alerts when TG Therapeutics, Inc.'s trials change

12 active trials 8 recruiting 4 Phase 3 3 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1
1
Phase 2
3
Phase 2/3
1
Phase 3
3
Not charted: 4 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT05877963 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of… Relapsing Multiple Sclerosis Recruiting 2026-09-21
NCT04130997 An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis (RMS) Active, Not Recruiting 2026-09-23
NCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and… Relapsing Multiple Sclerosis Active, Not Recruiting 2026-09-21
Phase 2/3
NCT07220252 Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of… Relapsing Multiple Sclerosis Recruiting 2026-09-21
Phase 2
NCT07680946 Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With… Schizophrenia Recruiting 2026-09-23
NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following… Myasthenia Gravis Recruiting 2026-09-22
NCT07503873 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… Multiple Sclerosis Recruiting 2026-09-21
Phase 1
NCT06680037 A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With… B-cell Mediated Autoimmune Disorders Recruiting 2026-09-09
Not specified
NCT06433752 A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI®… Relapsing Multiple Sclerosis Recruiting 2026-09-23
NCT06433765 A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes… Multiple Sclerosis Recruiting 2026-09-21
NCT06143514 A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk Relapsing Multiple Sclerosis Active, Not Recruiting 2026-09-24
NCT07577583 Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel B-cell Mediated Autoimmune Disorders Not Yet Recruiting 2026-05-11

Disease areas by active trials

Multiple Sclerosis (8) · Myasthenia Gravis (1) · Schizophrenia (1)

Get alerts when TG Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free